Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

U.S. health secretary Robert F. Kennedy Jr.'s changes to federal vaccine policy are prompting medical organizations and ...

A single shot during pregnancy is proving to be a powerful shield for newborns against one of the most common and dangerous viruses for infants: RSV. In a new UK study, babies whose mothers received t ...

The move targets thimerosal, a preservative that anti-vaccine activists blame for neurodevelopmental disorders, despite ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

It’s not surprising that, of all the recommendations the U.S. CDC’s vaccine advisory board made at its June meeting, the first one Health and Human Services Secretary Robert Kennedy signed off on ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.